About
GRAIL is a pioneering healthcare company on a mission to reduce the global burden of cancer through cutting-edge AI-driven early detection. Its flagship product, the Galleri® test, is a multi-cancer early detection (MCED) blood test that uses advanced next-generation sequencing (NGS), population-scale clinical data, and state-of-the-art machine learning algorithms to identify signals associated with more than 50 types of cancer—many of which have no recommended screening tests today. The test works by analyzing cell-free DNA shed by cancer cells into the bloodstream, using AI models trained on massive datasets to distinguish cancerous from non-cancerous signals with high specificity. When a cancer signal is detected, the Galleri test can also predict the cancer's origin tissue, helping guide physicians toward targeted diagnostic follow-up. GRAIL has conducted large-scale clinical studies, including the landmark NHS-Galleri Trial in England with over 140,000 participants, demonstrating substantial reductions in late-stage (Stage IV) diagnoses and a fourfold higher cancer detection rate versus standard-of-care alone. The test is designed for adults aged 50 and older and is ordered through a healthcare provider. GRAIL's technology integrates bioinformatics, automation, and proprietary AI software to make population-level cancer screening practical and scalable. It is aimed at healthcare systems, employers, insurance providers, and individual patients seeking proactive cancer screening beyond traditional methods.
Key Features
- Multi-Cancer Early Detection: The Galleri test screens for signals associated with 50+ cancer types in a single blood draw, including many with no currently recommended screening tests.
- AI-Powered Signal Classification: Uses advanced machine learning models trained on population-scale genomic data to accurately identify cancer signals and predict tissue of origin.
- Next-Generation Sequencing (NGS): Analyzes cell-free DNA in the bloodstream using NGS technology to detect methylation patterns unique to cancer cells.
- Tissue of Origin Prediction: When a cancer signal is detected, the test predicts where the cancer likely originated, helping guide physicians to the right diagnostic pathway.
- Large-Scale Clinical Validation: Backed by the NHS-Galleri Trial (140,000+ participants) and multiple peer-reviewed studies demonstrating real-world effectiveness and safety.
Use Cases
- Employer and insurance wellness programs offering multi-cancer early detection screening as a workplace or member benefit.
- Primary care providers adding the Galleri test to annual wellness visits for patients aged 50+ as a complement to existing cancer screenings.
- Health systems seeking to improve population-level cancer detection rates and reduce the proportion of late-stage diagnoses.
- Oncologists and clinicians using the tissue-of-origin prediction to guide diagnostic workups when a cancer signal is detected.
- Clinical researchers and biopharma partners studying multi-cancer early detection in large-scale prospective trials.
Pros
- Broad Cancer Coverage: Screens for 50+ cancer types in one test, filling critical gaps where no standard screening guidelines exist today.
- Clinically Validated at Scale: Supported by one of the largest cancer screening trials ever conducted, with results published and presented at major medical conferences.
- Non-Invasive and Convenient: Requires only a routine blood draw, making it accessible and easy to add alongside standard annual wellness visits.
Cons
- Does Not Detect All Cancers: The Galleri test does not detect a signal for all cancer types, and false positive or false negative results can occur.
- Requires Physician Order: Patients cannot self-order the test; it must be prescribed by a licensed healthcare provider, limiting direct consumer access.
- Cost and Insurance Coverage: As a paid test not yet universally covered by insurance, out-of-pocket costs may be a barrier for some patients.
Frequently Asked Questions
What is the Galleri test?
The Galleri test is a multi-cancer early detection (MCED) blood test developed by GRAIL that uses AI and next-generation sequencing to screen for signals from 50+ cancer types before symptoms appear.
How does GRAIL use AI in cancer detection?
GRAIL uses machine learning models trained on large-scale genomic datasets to identify DNA methylation patterns in cell-free DNA found in the blood, distinguishing cancer-associated signals from normal signals with high specificity.
Who should consider the Galleri test?
The Galleri test is designed primarily for adults aged 50 and older who want proactive cancer screening, especially for cancer types that lack standard recommended screening tests.
What does the NHS-Galleri Trial show?
The NHS-Galleri Trial enrolled over 140,000 participants in England and demonstrated a substantial reduction in Stage IV cancer diagnoses, increased early-stage detection, and a fourfold higher cancer detection rate compared to standard care alone.
Is the Galleri test available without a doctor's prescription?
No. The Galleri test must be ordered through a licensed healthcare provider. It is not available as a direct-to-consumer product.
